Jun 12, 2023 8:30am EDT Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Jun 08, 2023 9:00am EDT Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
May 17, 2023 8:00am EDT Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
May 09, 2023 4:01pm EDT Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
May 02, 2023 4:01pm EDT Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
May 02, 2023 7:30am EDT Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
Apr 13, 2023 7:30am EDT Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Mar 28, 2023 8:00am EDT Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
Mar 20, 2023 4:01pm EDT Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
